CLEAR-DE study to assess topical therapy for non-proliferative diabetic retinopathy
Category: News
Akari Therapeutics has reaffirmed its commitment to advancing research on PH1, a novel spliceosome modulator payload used in […]
Collaboration aims to advance next-generation therapeutics and vaccines
First patient dosed in phase 1b/2a study of procizumab
Irish biotech’s germ-free egg platform could help close global shortfall
GlueSEEKER enables rational design of targeted protein degraders
Clinical results from phase 2 study highlight analgesic effects in neuropathic pain patients
EC grants conditional marketing authorisation to Merck and SpringWorks Therapeutics
First patient dosed in BUOY-1 study targeting MDD with or without anxious distress
